Sophorolipid: a glycolipid biosurfactant as a potential therapeutic agent against COVID-19

Amita Daverey; Kasturi Dutta; Sanket Joshi; Achlesh Daverey

doi:10.1080/21655979.2021.1997261

journal article Open Access Dec 14, 2021

Sophorolipid: a glycolipid biosurfactant as a potential therapeutic agent against COVID-19

Amita Daverey

Kasturi Dutta

Sanket Joshi Achlesh Daverey

Bioengineered Vol. 12 No. 2 pp. 9550-9560 · Informa UK Limited

View at Publisher Save 10.1080/21655979.2021.1997261

Topics

No keywords indexed for this article. Browse by subject →

References

72

[1]

World Health Organization. (2020). Coronavirus disease (COVID-19) advice for the public. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public

[2]

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Alexander E. Gorbalenya, Susan C. Baker, Ralph S. Baric et al.

Nature Microbiology 10.1038/s41564-020-0695-z

[3]

10.1001/jama.2020.2648

[4]

10.1111/joim.13091

[5]

Guo YR. Military Med Res (2019)

[6]

10.1056/nejmc2004973

[7]

10.1073/pnas.2018995118

[8]

10.1016/s0140-6736(21)00869-2

[9]

Prompetchara E Asian Pac J Allergy Immunol (2020)

[10]

Yousefifard M Arch Acad Emergency Med (2020)

[11]

Centers for Disease Control and Prevention (CDC). Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) 2021; Updated on 16 February 2021. cited 2021 Aug 03. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

[12]

National Institutes of Health (NIH). USA. COVID-19 Treatment Guidelines. 2021; cited 2021 Aug 03. https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/

[13]

10.1186/s12985-021-01578-0

[14]

World Health Organization. Coronavirus disease (COVID-19): hydroxychloroquine. Dated 30 April, 2021. 2021b; cited 2021 Aug 03. https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-hydroxychloroquine

[15]

World Health Organization. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. 31 March 2021.2021c; cited 2021 Aug 03. https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials

[16]

10.1128/aac.00483-20

[17]

10.26633/rpsp.2020.40

[18]

Baglivo M Acta Biomed (2020)

[19]

10.1016/j.jece.2020.104754

[20]

10.3390/v13020322

[21]

Smith ML Front Microbiol (2020) 10.3389/fmicb.2020.00001

[22]

10.1016/j.coesh.2020.09.002

[23]

10.1080/21655979.2020.1853391

[24]

10.1007/s00253-018-9434-2

[25]

10.1016/j.tips.2013.10.002

[26]

10.3390/ijms12010633

[27]

10.1016/j.jclepro.2020.124406

[28]

10.1007/s10989-006-9041-4

[29]

10.1016/j.micpath.2021.104910

[30]

10.1007/s10570-019-02925-9

[31]

10.1016/j.colsurfb.2010.04.002

[32]

Elshafie AE Front Microbiol (2015)

[33]

10.1007/s13346-020-00750-3

[34]

10.1002/jmr.2188

[35]

10.1007/s11157-019-09502-3

[36]

10.1007/s00253-005-0243-z

[37]

10.1016/j.biortech.2019.121314

[38]

10.1039/c9ra07599b

[39]

10.1016/j.colsurfb.2021.112057

[40]

Sen S Front Microbiol (2020) 10.3389/fmicb.2020.00001

[41]

10.1016/j.bcab.2019.101287

[42]

10.1016/j.seppur.2020.116897

[43]

10.1093/femsyr/foy072

[44]

10.1007/bf02931436

[45]

10.1021/bc060094n

[46]

Gross RA, Shah V. 2007. Anti-herpes virus properties of various forms of sophorolipids. In World patent 2007130738 A1.

[47]

Gross RA, Shah V, Doncel GF. 2004. United States Patent Application Publication Pub. No .: US 2004/0121015 A1.

[48]

10.1128/aac.49.10.4093-4100.2005

[49]

10.1007/s12223-015-0413-z

[50]

Mohamed SK Indian J Pharmacol (2018)

Showing 50 of 72 references

Cited By

46

Sophorolipids: A comprehensive review on properties and applications

Srija Pal, Niloy Chatterjee · 2023

Advances in Colloid and Interface S...

Current advances in the classification, production, properties and applications of microbial biosurfactants – A critical review

Ayesha Kashif, Ramla Rehman · 2022

Advances in Colloid and Interface S...

Metrics

46

Citations

72

References

Details

Published: Dec 14, 2021
Vol/Issue: 12(2)
Pages: 9550-9560
License: View

Authors

A

Amita Daverey

Department of Neurosurgery, University of Nebraska Medical Center, Omaha, NE, USA

K

Kasturi Dutta

Department of Biotechnology and Medical Engineering, National Institute of Technology, Rourkela, India

S

Sanket Joshi

Oil & Gas Research Center, Central Analytical and Applied Research Unit, Sultan Qaboos University, Muscat, Oman

A

Achlesh Daverey

School of Environment and Natural Resources, Doon University, Dehradun, India; School of Biological Sciences, Doon University, Dehradun, India

Funding

NO FUNDING

Cite This Article

Amita Daverey, Kasturi Dutta, Sanket Joshi, et al. (2021). Sophorolipid: a glycolipid biosurfactant as a potential therapeutic agent against COVID-19. Bioengineered, 12(2), 9550-9560. https://doi.org/10.1080/21655979.2021.1997261

Sophorolipid: a glycolipid biosurfactant as a potential therapeutic agent against COVID-19

You May Also Like